Unlike everyday supplements stocked in every health store, CJC-1295 is distributed via a specialist research supply market that Creel residents navigate through international suppliers. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers more rigorous quality data than local retail ever could. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Creel researcher needs before placing a first order.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Creel researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
The most reliable path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums aggregate real purchasing experience that are more trustworthy than marketing materials. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger serious immune reactions even at trace quantities. Strong quality indicators beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Creel
COA-verified · International tracking · Research grade
All use of CJC-1295 in Creel or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. PubMed and related preprint servers provide the most complete literature coverage for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over conference abstracts or single case observations.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
